- Stocks
- Healthcare
- NYSE: ABBV

Price (delayed)

$166.41

Market cap

$293.96B

P/E Ratio

60.96

Dividend/share

$6.06

EPS

$2.73

Enterprise value

$340.53B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate

The debt has declined by 6% year-on-year and by 2.2% since the previous quarter

ABBV's P/E is 117% above its 5-year quarterly average of 28.1 and 50% above its last 4 quarters average of 40.6

The company's net income has shrunk by 59% YoY and by 25% QoQ

What are the main financial stats of ABBV

Market
Valuations
Earnings

Shares outstanding

1.77B

Market cap

$293.96B

Enterprise value

$340.53B

Price to earnings (P/E)

60.96

Price to book (P/B)

28.36

Price to sales (P/S)

5.42

EV/EBIT

42.97

EV/EBITDA

20.49

EV/Sales

6.27

Revenue

$54.32B

EBIT

$7.92B

EBITDA

$16.62B

Free cash flow

$22.06B

Per share
Balance sheet
Liquidity

EPS

$2.73

Free cash flow per share

$12.48

Book value per share

$5.87

Revenue per share

$30.72

TBVPS

$26.48

Total assets

$134.71B

Total liabilities

$124.31B

Debt

$59.39B

Equity

$10.36B

Working capital

-$4.84B

Debt to equity

5.73

Current ratio

0.87

Quick ratio

0.63

Net debt/EBITDA

2.8

Margins
Efficiency
Dividend

EBITDA margin

30.6%

Gross margin

62.4%

Net margin

9%

Operating margin

23.5%

Return on assets

3.6%

Return on equity

40%

Return on invested capital

13.2%

Return on capital employed

8.2%

Return on sales

14.6%

Dividend yield

3.64%

DPS

$6.06

Payout ratio

222%

How has the AbbVie stock price performed over time

Intraday

1.06%

1 week

2.54%

1 month

-7.38%

1 year

3.23%

YTD

7.38%

QTD

-8.62%

How have AbbVie's revenue and profit performed over time

Revenue

$54.32B

Gross profit

$33.9B

Operating income

$12.76B

Net income

$4.86B

Gross margin

62.4%

Net margin

9%

The company's net income has shrunk by 59% YoY and by 25% QoQ

The net margin has dropped by 56% year-on-year and by 24% since the previous quarter

The operating income has contracted by 30% YoY and by 15% from the previous quarter

The operating margin has declined by 25% year-on-year and by 14% since the previous quarter

What is AbbVie's growth rate over time

What is AbbVie stock price valuation

P/E

60.96

P/B

28.36

P/S

5.42

EV/EBIT

42.97

EV/EBITDA

20.49

EV/Sales

6.27

ABBV's P/E is 117% above its 5-year quarterly average of 28.1 and 50% above its last 4 quarters average of 40.6

The EPS has plunged by 59% YoY and by 25% from the previous quarter

AbbVie's equity has decreased by 40% YoY and by 14% from the previous quarter

ABBV's price to book (P/B) is 29% higher than its last 4 quarters average of 22.0

ABBV's P/S is 29% above its 5-year quarterly average of 4.2 and 13% above its last 4 quarters average of 4.8

ABBV's revenue is down by 6% year-on-year

How efficient is AbbVie business performance

AbbVie's return on assets has shrunk by 57% YoY and by 25% QoQ

The ROE has contracted by 46% YoY and by 15% from the previous quarter

The ROS has contracted by 45% YoY and by 18% from the previous quarter

AbbVie's ROIC has decreased by 42% YoY and by 16% from the previous quarter

What is ABBV's dividend history

DPS

$6.06

Dividend yield

3.64%

Payout ratio

222%

Recent dividends

How did AbbVie financials performed over time

AbbVie's total assets is 8% higher than its total liabilities

The quick ratio has contracted by 11% from the previous quarter and by 9% YoY

ABBV's current ratio is down by 9% since the previous quarter and by 9% year-on-year

The company's debt to equity has surged by 56% YoY and by 14% QoQ

AbbVie's equity has decreased by 40% YoY and by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.